EMA Invites Comments on Good Biomarker Practice
The European Medicines Agency (EMA) has released a consultation on good genomics biomarker practices.
The European Medicines Agency (EMA) has released a consultation on good genomics biomarker practices.
The outcome of the consultation will inform a guideline, which will set criteria to underpin the generation of robust clinical genomic datasets throughout a medicine’s lifecycle, the choice of genomic techniques and biomarkers, the impact on the relevant study design, and the appropriate level of analysis and reporting of genomic data. The goal is to enhance transparency, consistency, reproducibility and cross-validation between genomic-driven studies.
Comments on the paper are invited until October 31, 2014 and should be sent to pgwpsecretariat@ema.europa.eu.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
